RxDoctor Payments Data

Osama Haikal, MD

Gastroenterology · Las Vegas, NVNPI 1245348762

Payments from drug & device makers

What this record shows

The money is spread across several categories — gifts (54.6%), food and beverage and other — rather than concentrated in one kind of arrangement. Fujifilm Healthcare Americas Corporation accounts for 69.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $3,461 and has fallen 96.8% since, to $109 in 2025.

$6,906in general payments, 2019–2025

Across 127 payments — averaging $54.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fujifilm Healthcare Americas Corporation$5K
  • AbbVie$884
  • Ferring Pharmaceuticals Inc.$225
  • Johnson & Johnson$203
  • Takeda Pharmaceuticals U.S.A., Inc.$175
  • Sanofi$164
  • plus $481 from 8 others

What the payments were for

  • Food & beverage$2,09730%
  • Gifts$3,76855%
  • Other$1,04015%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,906 in reported general payments places this provider in the 65th percentile of 103 gastroenterology providers in Nevada.

See all gastroenterology providers in Nevada

Medicare billing

Part B allowed, 2024
$132,363
Medicare patients
438
Services billed
920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab30$207,160
CreonLipase/Protease/Amylase20$26,562
LinzessLinaclotide35$22,788
Mesalamine49$9,035
SutabSod Sulf/Pot Chloride/Mag Sulf44$7,291
ClenpiqSod Picosulf/Mag Ox/Citric Ac26$4,416
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates52$3,496
Mesalamine ErMesalamine36$3,193
Famotidine274$2,812
Budesonide DrBudesonide37$2,543
Omeprazole203$1,692
Pantoprazole Sodium236$1,576
Budesonide EcBudesonide11$1,458
Dicyclomine Hcl56$817
Hydrocortisone68$739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$884$49,35055 claims
Braintree Laboratories, Inc.Sutab$89$7,29144 claims
Ferring Pharmaceuticals Inc.Clenpiq$225$4,41626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 103 gastroenterology providers in Nevada.

Other gastroenterology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →